Audited Financial Result for quarter and Year ended 31 March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd reported audited FY25 results with nil revenue from operations and only Rs 64.02 lakh of other income (likely interest). The company posted a net loss of Rs 108.56 lakh in FY25, worsening from a Rs 73.61 lakh loss in FY24. Q4 FY25 showed a net profit of Rs 39.36 lakh mainly because other expenses were reclassified to a negative figure. The balance sheet was rebuilt through a preferential allotment of 1.36 crore equity shares that raised around Rs 24.66 crore, lifting cash from Rs 267 lakh to Rs 2,130 lakh and turning reserves positive at Rs 94.68 lakh. Operating cash flow stayed deeply negative at Rs (470.68) lakh versus Rs (20.85) lakh last year. The statutory auditor (PPN & Company, a new firm replacing the predecessor auditor) issued an unmodified opinion.
For shareholders, the company still has no operational business and continues to burn cash, so the turnaround story remains uncertain despite the clean balance sheet post capital infusion. Watch for any concrete business or acquisition plan utilising the raised funds.